iiinova — where your digital self keeps evolving

Niklas Klümper

@niklaskluemper.bsky.social

GU oncologist, Interested in precision oncology. ADC biomarker development. NECTIN4. Clinician Scientist. PI of translational research group at the University Hospital Bonn. Opinions are my own

Posts Replies Media

Niklas Klümper @niklaskluemper.bsky.social · 27/12/2024

Happy to share our manuscript titled 'Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy' published in JAMA Oncology! @jama.com jamanetwork.com/journals/jam...

jamanetwork.com

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy

This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.

150

Reposted by Niklas Klümper

Jarushka Naidoo @drjnaidoo.bsky.social · 26/12/2024

Can patterns of progression on IO, inform future decisions? -1377pts from 5 ph 3 trials used to create 3 PD risk levels - low (⬆️existing lesions), intermediate (new lesions), high (both) - risk score assoc w post-PD OS across tumors Prognostic, so far #LCSM jamanetwork.com/journals/jam...

jamanetwork.com

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy

This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.

0239

Reposted by Niklas Klümper

Markus Eckstein @markuseckstein3.bsky.social · 11/12/2024

Great review! NECTIN4 is an exciting target. More to come ! #cancer #jcoprecisionmedicine #bladdercancer #guoncology #biomarker

041

Reposted by Niklas Klümper

Todd Morgan, MD @wandering-gu.bsky.social · 05/12/2024

Awesome talk by @joshmeeks.bsky.social on trial design in NMIBC. Huge need to get away from single arm trials. #SUO24

1184

Niklas Klümper @niklaskluemper.bsky.social · 11/12/2024

Happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12… ➡️Patients with mUC with NECTIN4 amplifications (app. 25%) show remarkable responses to single-agent EV, with a 96% ORR compared to 32% in non-amplified cases! @ptarantinomd.bsky.social @markuseckstein3.bsky.social

051